-
Mashup Score: 0
Purpose Brain metastases (BM) remain a significant cause of morbidity and mortality in breast cancer (BC) patients. Specific factors promoting the process of BM and predilection for selected neuro-anatomical regions remain unknown, yet may have major implications for prevention or treatment. Anatomical spatial distributions of BM from BC suggest a predominance of metastases in the hindbrain and…
Source: SpringerLinkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 6Integrated Multidisciplinary Brain Metastasis Care Reduces Patient Visits and Shortens Time to Adjuvant Irradiation - 2 year(s) ago
PURPOSE: Timely surgical cavity stereotactic radiosurgery (SRS) is an important adjuvant to brain metastasis resection, with earlier treatment associated with less frequent recurrence. The logistical complexity of treatment organization, however, has resulted in suboptimal start times postsurgically. We implemented a process improvement approach to reduce the time from surgery to adjuvant…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#JCOOP #QualityInACTION: A streamline #multidisciplinary workflow for patients with surgically resected #brainmets reduced scans, visits and decreased time to #radiation start from 27 to 14 days with no wound healing complications. ➡️ https://t.co/b79Ivk5ENu @Dr_N_Moss https://t.co/7Ed2rJUCZt
-
-
Mashup Score: 1Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update Q and A - 2 year(s) ago
ASCO recently published an updated guideline for the management of advanced human epidermal growth factor receptor 2 (HER2)–positive breast cancer and brain metastases,1 along with a companion guideline on systemic therapy for patients with HER2-positive advanced breast cancer.2 Recent data on local therapy and systemic therapy advances for patients with HER2-positive advanced breast cancer and…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#JCOOP @ASCO Guideline Update #QandA: Management of Advanced #HER2–Positive #BreastCancer and #BrainMetastases. Given local tx and systemic tx advances, authors address selecting the appropriate treatment and surveillance regimens. ➡️ https://t.co/bepG4fFX4P #bcsm #brainmets https://t.co/c4xTGFprtx
-
-
Mashup Score: 1
The combination of paxalisib and radiotherapy exhibited complete or partial responses in all patients with brain metastases, according to interim data from an ongoing phase I clinical trial.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Paxalisib in combination with radiotherapy demonstrated complete or partial responses in all patients with brain metastases, according to interim data from an ongoing phase I clinical trial. #brainmets #cancer https://t.co/fRzX9VS55n
-
-
Mashup Score: 8
Purpose Broadening trial eligibility to improve accrual and access and to better reflect intended-to-treat populations has been recognized as a priority. Historically, patients with brain metastases have been understudied, because of restrictive eligibility across all phases of clinical trials. Meth …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Until recently, people with cancer & #brainmets were excluded from #OncTwitter #clinicaltrials. That era has ended. Best practices from academic, industry, pt #advocacy, & #regulatory perspective here: https://t.co/z2kPmcoQmH. https://t.co/LSFmFeS2Ae
-
-
Mashup Score: 2
A Conversation With Priscilla K. Brastianos, MD, PhD By Ronald Piana Posted: 7/18/2022 1:38:00 PM Last Updated: 7/18/2022 12:48:41 PM The effective treatment of patients with brain metastases is an unmet need because, until fairly recently, patients with brain metastases were excluded from…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Deciphering the Elusive Origin and Pathways of Brain Metastases: A Conversation With Priscilla K. Brastianos, MD, PhD https://t.co/LHbVKTqs4m #oncology #btsm #brainmets @MassGeneralNews https://t.co/KsF7olpAdY
-
-
Mashup Score: 0Strides Are Being Made in the Treatment of Brain Metastases From Breast Cancer - The ASCO Post - 2 year(s) ago
By Caroline Helwick Posted: 7/6/2022 12:54:00 PM Last Updated: 7/6/2022 11:57:52 AM New drugs for HER2-positive breast cancer are able to overcome some of the obstacles that have made brain metastases challenging to treat, according to Mark Pegram, MD, the Susy Yuan-Huey Hung Professor of Oncology at…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Strides Are Being Made in the Treatment of Brain Metastases From Breast Cancer https://t.co/gV02mJjjms #bcsm #BreastCancer #BrainMets #oncology
-
-
Mashup Score: 9Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update - 2 year(s) ago
PURPOSE To provide updated evidence- and consensus-based guideline recommendations to practicing oncologists and others on the management of brain metastases for patients with human epidermal growth factor receptor 2 (HER2)–positive advanced breast cancer up to 2021. METHODS An Expert Panel conducted a targeted systematic literature review (for both systemic therapy for non-CNS metastases and for…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 Just published in #JCO: Guideline update on management of advanced human epidermal growth factor receptor 2–positive #breastcancer and #brainmetastases. Read more ➡️ https://t.co/fz0lfJE8zb #bcsm #btsm #brainmets https://t.co/C7tyCsVGR7
-
-
Mashup Score: 9Trastuzumab Deruxtecan in Patients with Central Nervous System Involvement from HER2-Positive Breast Cancer: The DEBBRAH Trial - 2 year(s) ago
AbstractBackground. Trastuzumab deruxtecan (T-DXd) has shown durable antitumor activity in pretreated patients with HER2-positive advanced breast cancer (ABC),
Source: OUP AcademicCategories: Hem/Oncs, Latest HeadlinesTweet-
Include patients with #brainmets in #OncTwitter #clinicaltrials. You take a greater #drugdevelopment risk not doing it in 2022. 👇 https://t.co/YFNotMGROd
-
-
Mashup Score: 3
Purpose Broadening trial eligibility to improve accrual and access and to better reflect intended-to-treat populations has been recognized as a priority. Historically, patients with brain metastases have been understudied, because of restrictive eligibility across all phases of clinical trials. Meth …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Here's advice on why & how to include patients with #brainmets in #clinicaltrials, including early in #drugdevelopment & in some cases those with active CNS mets: https://t.co/nK00pq4a53. No paywall. #drugdevelopment #advocacy #OncTwitter cc @nlinmd @DrEdKim
-
.@USCBTC, @USCViterbi and @uscnorris created a novel methodology for analyzing spatial distribution of #brainmets from breast cancer. Their findings suggest a relationship between metastasis microenvironment and tumorigenesis. @doctorzada https://t.co/DvxFd9bGX1 https://t.co/1KkERNjKbp